Hereditary angioedema: an update on causes, manifestations and treatment.
Journal
British journal of hospital medicine (London, England : 2005)
ISSN: 1750-8460
Titre abrégé: Br J Hosp Med (Lond)
Pays: England
ID NLM: 101257109
Informations de publication
Date de publication:
02 Jul 2019
02 Jul 2019
Historique:
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
30
1
2020
Statut:
ppublish
Résumé
Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway. Since laryngeal oedema can be life-threatening as a result of asphyxiation, correct diagnosis and management of hereditary angioedema is vital. Hereditary angioedema attacks are mediated by bradykinin, the production of which is regulated by C1-INH. Hereditary angioedema therapy relies on treatment of acute attacks, and short- and long-term prophylaxis. Acute treatment options include C1-INH concentrate, icatibant and ecallantide. Self-administration of treatment is recommended and is associated with increased quality of life of patients with hereditary angioedema. Advances in diagnosis and management have improved the outcomes and quality of life of patients with hereditary angioedema.
Identifiants
pubmed: 31283393
doi: 10.12968/hmed.2019.80.7.391
doi:
Substances chimiques
Complement C1 Inhibitor Protein
0
Peptides
0
ecallantide
5Q6TZN2HNM
icatibant
7PG89G35Q7
Factor XII
9001-30-3
Kallikreins
EC 3.4.21.-
Bradykinin
S8TIM42R2W
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM